Venous Stenting Evaluation in Patients With Intracranial Hypertension Under Long-term Acetazolamide
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study is aimed at patients suffering from long term intracranial hypertension (caracterized by visual loss, chronic headache and/or tinnitus), receiving acetazolamide for more than 1 year, having inadequate response to treatment (untolerable side effects or insufficient efficacy). The goal is to evaluate if stenting of a specific vein in the brain could decrease the hypertension and improve associated symptoms. Patients will be randomly assigned in either best medical care group (recommended medication associated with weight loss) or interventional group (best medical care + stenting of the specific vein) and will undergo specific follow-up visits after 1, 3 and 12 months.
Eligibility Criteria
Inclusion Criteria: 1. Subject is ≥ 18 years old at inclusion. 2. Subject with definite diagnosis of IIH satisfying the modified Dandy criteria (A to E) ) at the time of initial diagnosis, under BMM including ACZ for more than 1 year 3. Patient with elevated intracranial pressure defined as \> 25 cm H20 or 18 mmHg 4. Subject with intracranial TVS stenosis on dominant transverse sinus and hypoplastic contralateral one (or bilateral TVS stenosis) diagnosed on MRI 5. Normal MRI findings excepted intracranial TVS stenosis or IIH related abnormalities 6. Patient having received information about data collection and having signed and dated an Informed Consent Form 7. Subjects must be able to attend all scheduled visits and to comply with all trial procedures 8. Subjects must be covered by public health insurance Exclusion Criteria: 1. Patients receiving topiramate in the previous month 2. Known contrast product, Nickel, titanium allergy 3. Exposure to an oral drug (other than ACZ), substance